Nabi Biopharmaceuticals Altastaph for the Prevention and Treatment of Staph. Aureus Infections
November 17, 2004 by admin · Leave a Comment
On Nov 17, 2004 Nabi Biopharmaceuticals released results from its Phase 2 clinical trial of Altastaph in premature or very low birth weight infants (infants weighing between 500 and 1500 grams). The company indicated that while the primary end-points of the study were met, an unexpectedly low rate of S. aureus infections in both the [...]
VaxGen’s rPA102 Recombinant Anthrax Vaccine
April 15, 2004 by admin · Leave a Comment
On April 15, 2004 VaxGen, Inc. announced that it had started the Phase II clinical testing of rPA102, its recombinant anthrax vaccine. VaxGen indicated that this 13-month trial is one of two studies under a $80.3 million agreement with the NIH’s National Institute of Allergy and Infectious diseases. The purpose of this study, involving 480 [...]
OraQuick Rapid HIV Antibody Test
March 26, 2004 by admin · Leave a Comment
On March 26, 2004 OraSure Technologies, Inc. announced that it has received U.S. Food and Drug Administration approval of its OraQuick® Rapid HIV Antibody Test for use with oral fluid. This would make OraQuick the first such test to receive FDA approval in the U.S. The FDA-approved OraSure® Oral Specimen Collection Device is a generic [...]
Acomplia (rimonabant)
March 12, 2004 by admin · Leave a Comment
On March 9, 2004 Sanofi-Synthelabo announced preliminary Phase III results for Acomplia™ (rimonabant), in two clinical trials: the Stratus-US (smoking cessation) trial and the RIO-Lipids/weight loss (obesity) trial. The Stratus-US trial randomized 787 smokers who wanted to quit to use either a placebo, a 5-milligram daily dose of Acomplia or a 20-milligram daily dose, in [...]